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Propofol induces MAPK/ERK cascade dependant
expression of cFos and Egr-1 in rat hippocampal
slices
Srivatsan Kidambi1,2,3*, Joel Yarmush1, Yevgeny Berdichevsky2, Sangeetha Kamath1, Wayne Fong1,
Joseph SchianodiCola1
Abstract
Background: Propofol is a commonly used intravenous anesthetic agent, which produce rapid induction of and
recovery from general anesthesia. Numerous clinical studies reported that propofol can potentially cause amnesia
and memory loss in human subjects. The underlying mechanism for this memory loss is unclear but may
potentially be related to the induction of memory-associated genes such as c-Fos and Egr-1 by propofol. This
study explored the effects of propofol on c-Fos and Egr-1 expression in rat hippocampal slices.
Findings: Hippocampal brain slices were exposed to varying concentrations of propofol at multiple time intervals.
The transcription of the immediate early genes, c-Fos and Egr-1, was quantified using quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR). MAPK/ERK inhibitors were used to investigate the mechanism of
action. We demonstrate that propofol induced the expression of c-Fos and Egr-1 within 30 and 60 min of
exposure time. At 16.8 μM concentration, propofol induced a 110% increase in c-Fos transcription and 90%
decrease in the transcription of Egr-1. However, at concentrations above 100 μM, propofol failed to induce
expression of c-Fos but did completely inhibit the transcription of Egr-1. Propofol-induced c-Fos and Egr-1
transcription was abolished by inhibitors of RAS, RAF, MEK, ERK and p38-MAPK in the MAPK/ERK cascade.
Conclusions: Our study shows that clinically relevant concentrations of propofol induce c-Fos and down regulated
Egr-1 expression via an MAPK/ERK mediated pathway. We demonstrated that propofol induces a time and dose
dependant transcription of IEGs c-Fos and Egr-1 in rat hippocampal slices. We further demonstrate for the first time
that propofol induced IEG expression was mediated via a MAPK/ERK dependant pathway. These novel findings
provide a new avenue to investigate transcription-dependant mechanisms and suggest a parallel pathway of
action with an unclear role in the activity of general anesthetics.
Introduction
Propofol is the most commonly used intravenous gen-
eral anesthetic that has been proven to be highly effec-
tive due to its rapid onset and short recovery time after
injection. Because of these advantages, propofol is now
widely used both for general anesthesia and for sedation
with local anesthesia[1,2]. It is thought to act primarily
through the potentiation of g-aminobutyric acid (GABA-
A) receptor currents [3,4]. While the GABA-A depen-
dant mechanisms is well established, there is a growing
interest in elucidating secondary mechanisms that might
have long-lasting side effects [5,6]. Propofol has been
reported to produce amnesia in addition to sedation,
hypnosis and general anesthesia. The inhibition of long-
term potentiation (LTP) in the hippocampus has been
attributed to the amnesic effect of propofol[3,7,8].
However, the underlying cellular mechanisms for the
propofol inhibition of hippocampal LTP are poorly
understood.
Recent studies have reported the important role
played by the expression of rapidly inducible genes
known as immediate-early genes (IEGs) in long-term
potentiation (LTP) and memory consolidation [9]. Tran-
scription factors, such as c-Fos, Egr-1, Nurr1 and Arc
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have been found to play a role in learning, memory and
LTP [10,11]. Several commonly used anesthetic agents
such as midazolam and thiopental were shown to elicit
rapid and transient induction of several immediate early
genes in neurons, including c-Fos, Egr-1 and Jun B
[12,13]. However, the same studies demonstrated that
high concentrations of propofol did not affect the
expression of c-Fos, JunB or Egr-1 in culture [12,13]. In
contrast, Kozinn and co-workers showed that propofol
regulates the expression of c-Fos in hippocampal slices
via inhibition of N-methyl-D-aspartate (NMDA) recep-
tor activation of the extracellular signal-regulated kinase
(ERK) pathway [14,15], while Hamaya et al reported that
propofol increases the expression of c-Fos and Jun B in
the rat brain [16]. Recently we have also demonstrated
that propofol induces a time and dose dependant tran-
scription of the IEGs c-Fos and Egr-1 in neuronal cells
[17]. Therefore, the interaction between propofol and
these immediate early transcription factors is still under
debate.
In this study, we investigated the ability of propofol to
induce the transcription of c-Fos and Egr-1 in rat hippo-
campal brain slices. Using this system we demonstrate a
time and dose dependant transcription of c-Fos and
Egr-1. Remarkably, while 16.8 μM of propofol, corre-
sponding to plasma concentrations in general anesthesia,
induced a 110% increase in c-Fos transcription, higher
concentrations failed to induce any transcriptional
changes in c-Fos. In contrast, propofol down regulated
the expression of Egr-1 with increasing time and con-
centration. The changes in transcription of c-Fos and
Egr-1 relied on the p38 mitogen-activated protein kinase
(p38-MAPK)/ERK signaling cascade. These findings
provide a new avenue to investigate transcription-
dependant mechanisms and suggest a parallel pathway
of action with an unclear role in the activity of general
anesthetics.
Methods
Materials
All chemicals were purchased from Sigma (St Louis,
MO) unless otherwise indicated. Propofol was purchased
from AstraZeneca (Wilmington, DE). FTI-277 (RAS
Inhibitor-Cat # 344555), RAF1 Kinase Inhibitor I (Cat #
553008), U0126 (MEK Inhibitor-Cat # 662005),
PD98059 (ERK Inhibitor-Cat # 513000), and SB203580
(p38-MAPK Inhibitor-Cat # 559389), were purchased
from Calbiochem (San Diego, CA).
Hippocampal slices
Isolated hippocampi from postnatal day 7 Sprague-
Dawley rat pups (Harlan Laboratories) were cut into
350 μm slices on a McIlwain tissue chopper (Mickle Lab
Eng. Co., Surrey, UK). 15-17 hippocampal slices were
prepared from each pup. Each data point in an experi-
mental group represents one slice from one animal.
Slices were placed into a 6-well plate that was filled
with just enough artificial cerebrospinal solution (ACSF,
composed of 120 mM NaCl, 3.3 mM KCl, 1.25 mM
NaH2PO4, 26 mM NaHCO3, 1.3 mM CaCl2, 0.9 mM
MgCl2, and 10 mM glucose in deionized water) to cover
the bottom of each well. At this stage the brain slices
were left untreated (negative control), treated with intra-
lipid (vehicle control) or treated with increasing concen-
trations of propofol ranging from 5.6 to 112.2 μM
propofol in ACSF and incubated in the interface config-
uration described above in a humidified 5% CO2 incuba-
tor at 37°C. The transcription of c-Fos and Egr-1 genes
was measured at several time intervals post treatment.
All animals were treated in accordance with National
Research Council guidelines and approved by the Sub-
committee on Research Animal Care at the Massachu-
setts General Hospital.
Real-Time Quantitative Reverse Transcriptase
Analysis of c-Fos and Egr-1 transcription was carried
out using Mx3000P QPCR system (Stratagene, La Jolla,
CA). RNA from the cells was extracted and purified
using a Qiagen’s Nucleospin RNA II kit (Valencia, CA)
and quantified using Nanodrop ND-1000 (Wilmington,
DE). 100 ng of total mRNA was reverse transcribed to
cDNA using a Superscript Platinum Two-Step qRT-PCR
kit from Invitrogen Life Technologies (Carlsbad, CA)
and amplified in a Perkin Etus Thermal Cycler 480.
Reported values were normalized to the internal stan-
dard actin. The primer sequences were as follows: c-Fos,
(forward) 5′-GAAGGAACCAGACAGGTCCA, (reverse)
5′-TCACCCTGCCTCTTCTCAAT (with expected pro-
duct size of 381 bp); Egr1, (forward) 5′- AGCGAA-
CAACCCTATGAGCA, (reverse) 5′-TCGTTTGGCT
GGGATAACTC (with expected product size of 345 bp);
Actin, (forward) 5′- GTCGTACCACTGGCATTGTG,
(reverse) 5′-CTCTCAGCTGTGGTGGTGAA.
Statistics
Data were analyzed using two-way ANOVA (for Figure 1)
and the Student’s t-test (for Figures 2 and 3). Results are
presented as means ± standard deviation and P values
< 0.05 were considered statistically significant.
Results
To investigate the effect of propofol on the transcription
of c-Fos and Egr-1, we exposed the hippocampal slices
to varying concentrations of propofol at increasing time
intervals. The transcription of c-Fos (Figure 1A) peaked
between 30 and 60 min of exposure and rapidly
returned to control levels while the transcription of
Egr-1 (Figure 1B) decreased and reached the minimum
Kidambi et al. BMC Research Notes 2010, 3:201
http://www.biomedcentral.com/1756-0500/3/201
Page 2 of 6
at 240 min. Maximal induction of c-Fos occurred fol-
lowing 60 min stimulation with 16.8 μM propofol,
resulting in 110% ± 17% (P = 0.012, N = 3) increase in
transcription. Surprisingly, both lower and higher doses
of propofol resulted in a non-significant, but sub-
maximal induction of c-Fos transcription 24% ± 9% (P =
0.073, N = 3) and 43% ± 7% (P = 0.065, N = 3) increase
for 5.6 μM and 28.0 μM concentration respectively. In
contrast, propofol caused a time and concentration
dependant down regulation of Egr-1 transcription and
Figure 1 Time and dose dependant propofol induced (A) c-Fos and (B) Egr-1 transcription in brain slices. Transcription of c-Fos and Egr-
1 was quantified using qRT-PCR. Gene transcription is normalized to actin and non-treated controls. Data are presented as mean ± sd from
three independent experiments. * p < 0.05; ** p < 0.01 versus non-treated control.
Figure 2 Dose dependant expression of c-Fos and Egr-1 by propofol following 60 min stimulation. The transcription of c-Fos and Egr-1
was quantified using qRT-PCR. Gene transcription is normalized to actin and to non-treated controls. Data are presented as mean ± sd from
three independent experiments. * p < 0.05; ** p < 0.01 versus non-treated control.
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was completely inhibited at 60 min and remained
inhibited for up to 240 min for all concentrations. Clini-
cally relevant concentration of 16.8 μM propofol resulted
in 91% ± 4% fold (P = 0.006, N = 3) inhibition in Egr-1
transcription. Both lower and higher doses of propofol
resulted in significant decrease of Egr-1 transcription, 87%
± 5% (P = 0.032, N = 3) and 94% ± 3% (P = 0.008, N = 3)
decrease for 5.6 μM and 28.0 μM concentration
respectively.
To further probe the dose-dependence of c-Fos and
Egr-1 transcription on propofol concentration, we
exposed the hippocampal slices to increasing concentra-
tions of propofol for 60 min. Figure 2 shows that at
clinically relevant concentrations (16.8 μM) propofol
caused a 80% induction in c-Fos transcription, and a
91% decrease in the transcription of Egr-1. However, at
a dose of 112.2 μM, propofol did not significantly alter
c-Fos (13% ± 1.5% decrease; P = 0.188, N = 3) compared
to control. In contrast, propofol significantly reduced
the transcription of Egr-1 in all concentrations including
both lower concentration of 5.6 μM (85% ± 5% decrease;
P = 0.008, N = 3) and higher concentration of 112.2 μM
(93% ± 3% decrease; P = 0.007, N = 3). Further, clini-
cally relevant concentration of 16.8 μM propofol
resulted in 91% ± 4% (P = 0.006, N = 3) decrease in
Egr-1 transcription.
To evaluate the role of the MAPK/ERK signaling cas-
cade in the induction of c-Fos and Egr-1 expression we
exposed hippocampal slices pretreated with 10 μM FTI-
277 (RAS Inhibitor), 10 μM RAF1 Kinase Inhibitor I, 10
μM UO126 (MEK Inhibitor), 50 μM PD98059 (ERK
Inhibitor), or 10 μM SB203580 (p38-MAPK Inhibitor) to
propofol (Figure 3; Table 1). Pretreatment of hippocam-
pal slices with RAS, RAF, MEK, ERK or p38-MAPK inhi-
bitors for 60 min did not significantly change the
transcription of c-Fos or Egr-1. Stimulation of RAS
inhibitor pretreated hippocampal slices with 16.8 μM
propofol resulted in a significantly lower c-Fos (49% ±
12%; P = 0.024, N = 3) and higher Egr-1 (39% ± 7%;
P = 0.046, N = 3) gene transcription compared to propofol
treatment alone. Similarly, stimulation of hippocampal
slices pretreated with RAF, MEK, ERK or p38-MAPK inhi-
bitors with 16.8 μM of propofol resulted in a significantly
lower c-Fos and higher Egr-1 gene transcription compared
to propofol treatment alone, demonstrating the role of
Figure 3 Elucidating the mechanism of propofol-induced c-Fos and Egr-1 expression in hippocampus brain slices. The transcription of
c-Fos and Egr-1 was assessed using qRT-PCR. Brain slices with or without pretreatment of 10 μM FTI-277 (RAS Inhibitor), 10 μM RAF1 Kinase
Inhibitor I, 10 μM UO126 (MEK Inhibitor), 50 μM PD98059 (ERK Inhibitor), and 10 μM SB203580 (p38-MAPK Inhibitor), were stimulated with 16.8
μM propofol for 60 min and the expression of c-Fos and Egr-1 was measured using qRT-PCR. Data are presented as mean ± sd from three
independent experiments. * p < 0.05 versus control, + p < 0.05 versus propofol treatment.
Table 1 Gene expression of c-Fos and Egr-1 accessed
using RT-PCR
Conditions c-Fos Egr-1
Fold
change
P
value
Fold
change
P
value
Propofol 1.78 ± 0.17 0.09 ± 0.04
Propofol + RAS
inhibitor
0.51 ± 0.12 0.024 0.62 ± 0.09 0.046
Propofol + RAF
inhibitor
0.77 ± 0.08 0.041 0.67 ± 0.14 0.032
Propofol + MEK
inhibitor
0.74 ± 0.10 0.036 0.49 ± 0.09 0.029
Propofol + ERK inhibitor 0.66 ± 0.11 0.032 0.59 ± 0.08 0.044
Propofol + MAPK
inhibitor
0.62 ± 0.13 0.021 0.55 ± 0.14 0.037
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p38-MAPK/ERK signaling cascade in the propofol induc-
tion of the IEGs, c-Fos and Egr-1.
Discussion
The purpose of this study was to evaluate the effects of
propofol stimulation on c-Fos and Egr-1 gene transcrip-
tion in hippocampal brain slices at varying doses and
time intervals. Our data also suggests that the induction
of c-Fos and Egr-1 by propofol is mediated by the p38-
MAPK/ERK signaling cascade.
The data shows a time and dose dependant induc-
tion of c-Fos and Egr-1 expression in hippocampal
brain slices following exposure to propofol. These
results are especially interesting as previous reports
suggested that propofol did not affect the expression
of c-Fos and Egr-1 [12-15]. Kozinn and co-workers
demonstrated that lower concentrations of propofol
inhibits N-methyl-D-aspartate (NMDA) receptor acti-
vation of MAPK/ERK pathway and c-Fos transcription
in hippocampal neurons[14]. However, our work
demonstrates that propofol has a significant effect at
higher concentrations and when exposed to longer
time. In fact, in a clinical setting, propofol concentra-
tion in the plasma is about 16.8 μM [18], and at this
concentration the drug induced a 110% increased
expression of c-Fos and 90% decrease of Egr-1 tran-
scription. Jevtovic-Todorovic and co-workers demon-
strated that exposure of the developing brain to drugs
that block NMDA glutamate receptors or drugs that
potentiate GABA(A) receptors can induce apoptotic
neurodegeneration in the developing brain, deficits in
hippocampal synaptic function, and persistent mem-
ory/learning impairments[19]. Our results also suggest
that clinically relevant doses of propofol can potentially
induce long-term changes in neuronal function by
inducing changes in the gene expression.
Mitogen-activated protein kinases (MAPKs), a large
family of cytosolic and nuclear serine/threonine kinases,
have been implicated in the regulation of variety of cel-
lular and synaptic activities in neurons[20]. Specifically,
MAPKs form central signaling pathways processing
inducible gene expression in response to various forms
of extracellular and intracellular stimuli. The activation
of MAPK/ERK signaling pathway has been demon-
strated to be a critical molecular step toward the devel-
opment and/or maintenance of synaptic plasticity
including LTP and long-term depression (LTD) and
memory formation in the hippocampus[21-23]. Several
studies have shown that general anesthetics may inter-
fere with cellular targets, including MAPK/ERK path-
ways [14,24]. Previous reports suggest the involvement
of the MAPK/ERK pathway in the induction of c-Fos
and Egr-1 expression by growth hormone[25] or mida-
zolam[12].
Our results demonstrate that inhibition of the MAPK/
ERK signaling cascade using RAS, RAF, MEK, ERK or
p38-MAPK inhibitors blocked the propofol-induced
c-Fos and Egr-1 expression, thus suggesting the possible
involvement of MAPK/ERK pathway in propofol-
induced immediate early gene expression. These
findings indicate a new avenue to explore a transcrip-
tion-dependant mechanism that may possibly underlie
anesthetic interference with synaptic plasticity related to
amnesic properties of intravenous anesthetics.
Conclusion
In summary, we demonstrated that propofol induces a
time and dose dependant transcription of IEGs c-Fos
and Egr-1 in rat hippocampal slices. We further demon-
strate for the first time that propofol induced IEG
expression was mediated via a MAPK/ERK dependant
pathway.
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